Education
About Us
Working with TipRanks
Follow Us
Precigen (PGEN)
NASDAQ:PGEN
PGEN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.65 - $2.17
Previous CloseN/A
Volume729.99K
Average Volume (3M)2.07M
Market Cap
$544.74M
Enterprise Value$238.41M
Total Cash (Recent Filing)$102.77M
Total Debt (Recent Filing)$212.26M
Price to Earnings (P/E)―
Beta2.07
Next Earnings
May 07, 2025EPS Estimate
-0.06Last Dividend Ex-Date
Jan 19, 2017Dividend YieldN/A
Share Statistics
EPS (TTM)-0.55
Shares Outstanding292,869,100
10 Day Avg. Volume2,140,793
30 Day Avg. Volume2,065,743
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)199.17
Price to Cash Flow (P/CF)-6.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.44
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.25K
Enterprise Value/Ebitda-1.75
Forecast
1Y Price Target
$6.33Price Target Upside257.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Precigen News
PremiumCompany Announcements
Precigen Secures $79M Financing for 2025 Launch
---
Bulls Say, Bears Say
Bulls Say
Market OpportunityManagement's market analysis indicates a multi-billion dollar market opportunity for PRGN-2012 in adult RRP patients alone.
Regulatory ApprovalThe FDA grants PRGN-2012 priority review, setting up a PDUFA date, indicating a faster-than-usual review process for the drug.
Bears Say
Financial StabilityThe Innovator 21 deal, netting $8.5 million in non-dilutive capital along with the $79 million PIPE, sufficiently addresses the balance sheet worries.
---
Ownership Overview
42.78% Insiders
12.73% Mutual Funds
12.65% Other Institutional Investors
26.21% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PGEN FAQ
What was Precigen’s price range in the past 12 months?
Precigen lowest stock price was $0.65 and its highest was $2.17 in the past 12 months.
What is Precigen’s market cap?
Precigen’s market cap is $544.74M.
When is Precigen’s upcoming earnings report date?
Precigen’s upcoming earnings report date is May 07, 2025 which is in 56 days.
How were Precigen’s earnings last quarter?
Currently, no data Available
Is Precigen overvalued?
According to Wall Street analysts Precigen’s price is currently Undervalued.
Does Precigen pay dividends?
Precigen pays a Notavailable dividend of $0.24 which represents an annual dividend yield of N/A. See more information on Precigen dividends here
What is Precigen’s EPS estimate?
Precigen’s EPS estimate is -0.06.
How many shares outstanding does Precigen have?
Precigen has 292,869,100 shares outstanding.
What happened to Precigen’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Precigen?
Currently, no hedge funds are holding shares in PGEN
---
Precigen Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.33 (257.63% Upside)
$6.33 (257.63% Upside)
Blogger Sentiment
Bullish
PGEN Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 13.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.3%
Last 30 Days ▲ 5.0%
Last 30 Days ▲ 5.0%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
1.14%
12-Months-Change
Fundamentals
Return on Equity
-137.46%
Trailing 12-Months
Asset Growth
-56.22%
Trailing 12-Months
Company Description
Precigen
Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It focuses on programming biological systems to alleviate disease, remediate environmental challenges, and provide sustainable food and industrial chemicals. The product pipeline includes Isobutanol, Isobutyraldehyde, Farnesene, and Isoprene. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.
---
PGEN Stock 12 Month Forecast
Average Price Target
$6.33
▲(257.63% Upside)
Technical Analysis
Sangamo Biosciences
―
Bluebird Bio
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Best Analysts Covering PGEN
1 Year
1 Year Success Rate
12/26 ratings generated profit
1 Year Average Return
+0.64%
reiterated a buy rating 15 days ago
Copying Jason Butler's trades and holding each position for 1 Year would result in 46.15% of your transactions generating a profit, with an average return of +0.64% per trade.
---